US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Novo Nordisk A/S B Shares ADRhedged

25.35

+0.11030.44%

Post-market: 25.350.00000.00%16:15 EDT

Volume:499

Turnover:12.63K

Market Cap:4.06M

PE:- -

High:25.35

Open:25.33

Low:25.33

Close:25.24

52wk High:34.36

52wk Low:19.00

Shares:160.00K

Float Shares:160.00K

Volume Ratio:0.57

T/O Rate:0.31%

Dividend:1.70

Dividend Rate:6.69%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Novo Nordisk’s AMAZE 9 Oral Obesity Trial: A New Pill in the Weight-Loss Race

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NVOH"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","market":"US","secType":"STK","nameCN":"Novo Nordisk A/S B Shares ADRhedged","latestPrice":25.35,"timestamp":1787601600000,"preClose":25.2397,"halted":0,"volume":499,"hourTrading":{"tag":"盘后","latestPrice":25.35,"preClose":25.35,"latestTime":"16:15 EDT","volume":8,"amount":202.8,"timestamp":1787602500263,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004370099486127105,"floatShares":160001,"shares":160001,"eps":0,"marketStatus":"Post-Mkt","change":0.1103,"latestTime":"08-24 19:51:51 EDT","open":25.33,"high":25.35,"low":25.33,"amount":12632,"amplitude":0.000792,"askPrice":37.8,"askSize":200,"bidPrice":18.29,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":25.2397,"nav":24.870799,"aum":3979352.710799,"dividendRate":0.066907,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.35,"preClose":25.35,"latestTime":"16:15 EDT","volume":8,"amount":202.8,"timestamp":1787602500263,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.570808,"impliedVol":0.111,"impliedVolPercentile":0.1},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","floatShares":160001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.570808,"shares":160001,"dividePrice":1.6961,"high":25.35,"amplitude":0.000792,"preClose":25.2397,"low":25.33,"week52Low":19,"pbRate":"--","week52High":34.36,"institutionHeld":0,"latestPrice":25.35,"committee":-0.333333,"eps":0,"divideRate":0.066907,"volume":499,"delay":0,"ttmEps":0,"open":25.33,"prevYearClose":27.4362,"prevWeekClose":25.2397,"prevMonthClose":25.407,"prevQuarterClose":26.0576,"fiveDayClose":24.4193,"twentyDayClose":27.1084,"sixtyDayClose":25.1269},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"NVOH","amount":0.76666,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"NVOH","amount":0.27495,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"NVOH","amount":0.48798,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2025-09-16","symbol":"NVOH","amount":0.16566,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"Novo Nordisk A/S (B Shares) ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-23","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOH\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-16","recordDate":"2025-09-16","paymentDate":"2025-09-23","value":0.16566,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.48798,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.27495,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.76666,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOH\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662270747","title":"Novo Nordisk’s AMAZE 9 Oral Obesity Trial: A New Pill in the Weight-Loss Race","url":"https://stock-news.laohu8.com/highlight/detail?id=2662270747","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662270747?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:31","pubTimestamp":1787589070,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) has launched AMAZE 9, a Phase 3 obesity study title...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-amaze-9-oral-obesity-trial-a-new-pill-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-amaze-9-oral-obesity-trial-a-new-pill-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVO","LU1093756168.USD","BK4007","LU0154236417.USD","LU1093756325.SGD","BK4588","THNR","IE00BZ1G4Q59.USD","BK4585","NVOC","OZEM","NVOH","IE00BKVL7J92.USD","BK4532","BK4599","PPH","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662270631","title":"Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2662270631","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662270631?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:02","pubTimestamp":1787587320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B dropped 0.5% to DKK299.25 Monday on what proved to be an overall unfavorable trading session for the stock market, with the OMX Nordic 40 Index falling 0.3% to 2,710.02.The company closed DKK110.70 below its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 3,241,705, compared to the 50-day average trading volume of 4,317,428.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOC","NVOH","BK4599","PPH","BK4532","BK4588","BK4007","THNR","LU0154236417.USD","BK4585","NVO","NVOX","IE00BKVL7J92.USD","OZEM","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661727717","title":"Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2661727717","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661727717?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:18","pubTimestamp":1787584692,"startTime":"0","endTime":"0","summary":"Novo Nordisk ( ($NVO) ) has issued an announcement. On 6 May 2026, Novo Nordisk launched a share repurchase programme under EU Safe Harbour rules a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-details-progress-in-dkk-15-billion-share-buyback-programme-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-details-progress-in-dkk-15-billion-share-buyback-programme-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD","NVOX","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","PPH","BK4588","NVOC","LU0154236417.USD","THNR","OZEM","NVO","BK4007","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271595","title":"Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271595","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271595?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:12","pubTimestamp":1787577120,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals has earned a third $10 million milestone payment from Novo Nordisk for hitting a key milestone in the clinical development program for its obesity drug.The biopharmaceutical company on Monday said that it has achieved a patient dosing milestone in the continuing phase 1 program for LX9851, a treatment being developed for obesity and associated metabolic disorders.Lexicon and Novo Nordisk signed an exclusive worldwide license agreement for LX9851 last year, under which Novo Nordisk is able to develop, manufacture and commercialize the drug for all indications.So far, Lexicon has earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its Novo Nordisk collaboration. Lexicon is also entitled to receive tiered royalties on future LX9851 sales.The development program for LX9851 was kicked off by Novo Nordisk in March to investigate the safety, tolerability, pharmacokinetics and pharmacodynam","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKVL7J92.USD","BK4585","BK4532","NVOC","BK4007","LU0154236417.USD","OZEM","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4599","LXRX","NVOH","PPH","LU1093756168.USD","THNR","NVO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":50,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOH\",params:#limit:6,delay:false,,,undefined,":[]}}